Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 07 2025
0mins
Source: Businesswire
Clinical Study Announcement: Cyclo Therapeutics presented data from its Pivotal Phase 3 global study, TransportNPC™, evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 at the WORLD Symposium in San Diego, highlighting encouraging preliminary findings and ongoing efforts to address this rare disease.
Future Prospects: The company anticipates interim data readout in H1 2025 and aims to submit marketing applications based on positive results, while also navigating a merger with Rafael Holdings to enhance its capabilities in developing treatments for rare diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
